Your browser doesn't support javascript.
loading
Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
Boneu, B; Navarro, C; Cambus, J P; Caplain, H; d'Azemar, P; Necciari, J; Duret, J P; Gaud, C; Sié, P.
Affiliation
  • Boneu B; Laboratoire de Recherche sur l'Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France.
Thromb Haemost ; 79(2): 338-41, 1998 Feb.
Article in En | MEDLINE | ID: mdl-9493587
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thrombophlebitis / Nadroparin / Factor Xa Inhibitors / Anticoagulants Type of study: Clinical_trials Limits: Adolescent / Adult / Humans Language: En Journal: Thromb Haemost Year: 1998 Document type: Article Affiliation country: Francia Country of publication: Alemania
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thrombophlebitis / Nadroparin / Factor Xa Inhibitors / Anticoagulants Type of study: Clinical_trials Limits: Adolescent / Adult / Humans Language: En Journal: Thromb Haemost Year: 1998 Document type: Article Affiliation country: Francia Country of publication: Alemania